ProfoundBio’s Post

Interesting article about the work being done by Enlaza Therapeutics developing covalent biologics for enhanced cancer treatments with fewer side effects. Seems like something that has a lot of potential - interested to see where they go with this! #Oncology #Innovation #HealthcareEvolution #Biotech #Biotechnology

evitria’s journal club - paper of the week no. 11 Antibody Conjugates - Recent Advances and Future Innovations (Jan 2020) from Donmienne Leung et al. Dive into the dynamic world of ADCs with this review! Discover the various formats, conjugations, and payloads revolutionizing oncology treatments and glimpse the future of non-oncology applications. A must-read for enthusiasts in the field! 🧬💊 Want to learn more about how evitria can support your biologics development work? Get in touch today: www.evitria.com/contact #antibodies #research #antibodydrugconjugates

I am sure many of you are thinking: "Ugh, not more ADCs, that's so passe." But not so fast, folks! There is so much more that a conjugated biologic, antibody or antibody-like molecule (or peptide, small molecule, etc.) could do, from novel payloads like degraders to immunotherapies, to hitting novel targets such as internal proteins, to delivering antigens to APCs. So please join me and my colleague, Viraj Parekh along with our esteemed panelists Greg Dwyer, Asthika Goonewardene, John Lambert, Michael G King Jr, Jeremy Sauer and Michael Stumpp as we take ADCs "To the Next Level." #cancer #oncology #ADCs #antibodies #biotech #pharma

⁤EV Engineering for Targeted Cancer Therapy: Enhancing Efficacy and Precision. The review article by Ren et al. from Frontiers in Bioengineering and Biotechnology, present opportunities for innovation in drug delivery systems, highlighting several advancements and methodologies pertinent to EV production, modification, purification, and drug loading that could drive strategic development in therapeutic applications. Article link: https://lnkd.in/gYdnsAc8 #ExtracellularVesicles #DrugDevelopment #Oncology #Pharmaceuticals

Our latest blog post is here to guide you step-by-step through your Kinase Inhibitor Development. From identifying targets to optimizing compounds, we've got you covered. Take your understanding of kinase drug discovery to the next level. Click the link below to access our comprehensive guide and elevate your expertise in the field. Let's accelerate your kinase inhibitor to the clinic together! 🔬💡 #biotech #drugdiscovery #kinaseinhibitors #oncology #pharma #innovation Step-by-Step Guide to Kinase Inhibitor Development - Reaction Biology 📚🔗 https://hubs.ly/Q02FNrGf0

Any insights? MAB used in the treatment of metastatic colorectal cancer, brain tumor (glioblastoma multiforme), which will be introduced to the Turkish market in the middle of 2026. #marketintelligence #competitiveintelligence #marketsmind #mabxience #Abdiİbrahim

Hello, Beautiful Lake Velence! It was exciting to be a guest speaker at a team-building event for a leading pharmaceutical company. I had the opportunity to share with 100+ professionals how computational solutions can change how we can clinically develop faster and safer molecularly targeted therapies in precision oncology. It is a new dawn in cancer research and drug discovery, where, finally, we can reverse the current trend of fewer new drugs for most investments and accelerate the development of new medicines for patients who need them. #precisiononcology #artificalintelligence

Among various novel ADC’s platforms, Araris Biotech AG Biotech features their innovative linker technology, enabling payload attachment to “off-the-shelf” antibodies without needing to re-engineer or reduce antibodies. Now Araris Biotech AG is going to present their novel ADC molecule, armed with this platform, at the Late-Breaking Research Poster session of the upcoming AACR 2024 conference (April 5-10) in San Diego, titling “Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo”. According to their website, the “off-the-shelf” antibodies would be site (Q295) specifically conjugated with linker and payload through one step Enzymatic catalysis. Check link for more detail: https://lnkd.in/gArpUa2p https://lnkd.in/gmBKgNf Additionally, the 2024 Annual Conference of our society, featuring numerous novel modalities of biologics, will convene in Cambridge, MA, USA on Saturday, May 11, 2024. Registration for the conference is now open via the following link. https://lnkd.in/ecmFPA4v #antibodydiscovery #antibodydrugconjugates #oncology #annualmeeting #annualconference #aacr

Here, researchers use high-resolution #cryoEM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division. The study offers detailed insight into inhibitor interactions and networks, and the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based #DrugDesign.

Here, researchers use high-resolution #cryoEM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division. The study offers detailed insight into inhibitor interactions and networks, and the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based #DrugDesign.